The techniques of present-day cryosurgery performed with multiprobe freezing apparatus and advanced imaging techniques yield predictable and encouraging results in the treatment of prostatic and renal cancers. Nevertheless, and not unique to cryosurgical treatment, the rates of persistent disease demonstrate the need for improvement in technique and emphasize the need for proper management of the therapeutic margin. The causes of persistent disease often relate to a range of factors including selection of patients, understanding of the extent of the tumor, limitations of the imaging techniques, and failure to freeze the tumor periphery in an efficacious manner. Of these diverse factors, the one most readily managed, but subject to therapeutic error, is the technique of freezing the tumor and appropriate margin to a lethal temperature [Baust, J. G., Gage, A. A. The Molecular Basis of Cryosurgery. BJU Int 95, 1187-1191 (2005)]. This article describes the recent experiments that examine the molecular basis of cryosurgery, clarifies the actions of the components of the freeze-thaw cycle, and defines the resultant effect on the cryogenic lesion from a clinical perspective. Further, this review addresses the important issue of management of the margin of the tumor through adjunctive therapy. Accordingly, a goal of this review is to identify the technical and future adjunctive therapeutic practices that should improve the efficacy of cryoablative techniques for the treatment of malignant lesions.
The Tissue Response to Freezing
The response of tissue to cold injury ranges from inflammation to cellular destruction, depending upon the severity of the freezing. In cryosurgery, this difference is the basis for a selective therapeutic response. Minor freezing injury produces only an inflammatory response, which has some therapeutic uses, as in the treatment of retinal detachment. Severe freezing produces destruction of cells through the physical formation of ice within a cell. Some differences in the sensitivity of diverse cell types to cold injury have been reported and the differences may be exploited for therapeutic purposes, whether for destruction or preservation of cells and tissues (2) (3) (4) (5) (6) (7) (8) (9) . However, the cryosurgical treatment of tumors requires that the technique ensures cellular destruction.
The cryogenic lesion is characterized by coagulation necrosis in the central portion surrounded by a relatively thin peripheral zone (freeze margin) in which cell destruction is incomplete. Beyond this area is a zone that does not freeze, but becomes hypothermic. Soon after thawing, the tissue appears hyperemic, particularly about the border of the previously frozen volume, and congested in the central zone, which then becomes edematous. The extent of necrosis is evident after several days. The border of the previously frozen tissue (freeze margin) is critically important to therapeutic management. In this zone, where the tissue temperatures range from 0º to -20 ºC, some cells live, some cells die, and others hover between life and death (10, 11) . It is within this region that high numbers of apoptotic and secondary necrotic cells are evident. The therapeutic challenge is to ensure the death of cells in this region.
Repair of the injured tissue begins quickly. The initial response features new blood vessel formation and infiltration of inflammatory cells, penetrating the necrotic tissue. Over the following weeks to months, the necrotic tissue is slowly replaced by a fibrous scar of collagen laid down by fibroblasts. The preservation of the architecture (the collagenous matrix) of the tissues during freezing is an asset to tissue repair, and healing is usually favorable in comparison to heat-based thermal injuries.
The Mechanisms of Cryogenic Injury
The mechanism of tissue injury from freezing includes direct injury to the cells caused by ice crystal formation. Microcirculatory failure then develops after thawing. The cascade is completed with the induction of apoptosis and cellular necrosis. Ice crystal formation, especially in the peripheral region of the freeze zone, removes water from the cells, which in turn produces major deleterious metabolic disturbances related to solute concentration, the "solution effects". Ice crystals also cause mechanical damage due to cell membrane disruption and to shearing forces, especially in highly organized tissues. Intracellular ice crystal formation is surely lethal. The vascular stasis that develops soon after thawing is a major mechanism of injury. The loss of blood supply in the volume of previously frozen tissue increases the probability that the cells will not survive. While the relative importance of these two mechanisms of injury has long been debated, the two are clearly synergistic in cryoinjury leading to cell death from freezing (1, (12) (13) (14) (15) .
Recently, apoptosis or programmed cell death has been recognized as a mechanism of cell death associated with thermal injury (16) . In investigations with human prostate cancer cells in vitro, Hollister and associates described cells dying from apoptosis some days after freezing (17) . In this study, a series of experiments conducted in which an apoptotic inhibitor was present while cells were exposed to a range of temperatures from 37 ºC to -75 ºC. Cell viability assessment revealed that a significant percentage of cells were able to survive when exposed to freezing temperatures due to the inhibition of freeze-induced apoptosis (Figure 1 ). Further examination of the freeze-compromised cells revealed a clear demonstration of the classic characteristics of apoptosis, including nonrandom DNA cleavage, cell membranes with blebs, phospholipid inversion in the membrane, and caspase activation (18).
Experiments in vitro have shown that apoptosis occurs following exposure to modest freezing temperatures and that cells are susceptible to apoptotic initiation events up to 12-24 hours after thawing (19) (20) (21) . In the study by Clarke et al. (19) , prostate cancer cells were exposed to freezing (-15 ºC) and modes of cell death were evaluated over a 48 hour recovery period. Cell rupture and necrosis were prominent immediately post-thaw, while apoptotic cell death was most prominent 12-hours post-freeze ( Figure 2 ). This apoptotic death later was shown to be partially regulated through the disruption of the normal function of mitochondria within the cells. The mitochondria play an important role in the apoptotic death cascade, most notably through the influence of the Bcl-2 family of proteins, which are inhibitors of apoptosis. This family of proteins normally functions to maintain closure of the pores within the mitochondrial membrane. If the pores open, leakage of cytochrome c activates one path of the apoptotic cell death cascades.
Another study by Clarke et al. (22) demonstrated the proapoptotic Bax protein levels normally found in the cytoplasm increased immediately after the freezing insult while the anti-apoptotic Bcl-2 protein later increased around 12-hours post-thaw. Ratio metric analysis of Bcl-2 and Bax proteins revealed that immediately post-thaw, there was a mitochondrial-based signal promoting cell death, whereas by 12-hours post-thaw, this signal had shifted towards the pro-survival mode (Figure 3 ). It has further been demonstrated that in many cases Bcl-2 is over expressed in many kinds of cancer, including prostate, and that this over expression can protect the cancer cells from various therapeutic strategies (23-25). Over expression of Bcl-2 in vitro in a prostate cancer cell model did not affect the efficacy of cryoablation alone, but it 
Figure 1:
Effects of an apoptotic inhibitor on PC-3 cell viability following exposure to freezing. Cells were exposed to a range of temperatures from 37 ºC to -75 ºC with or without the presence of an apoptotic inhibitor. Cell viability was assessed 1 day post thaw using the metabolic activity indicator alamarBlue™. did protect the cells significantly when exposed to the combination consisting of Taxotere and freezing ( Figure 4 ). While few in vivo studies have been conducted thus far, the involvement of apoptosis is clear (26). An in vivo study using a human lung cancer cell line grafted into SCID mice, by Forest et al. (44) , demonstrated the induction of apoptosis following tumor freezing with peak levels of activity eight hours after thawing. In general terms, apoptotic cells are found primarily in the peripheral zone of a cryogenic lesion where the freezing temperatures are not sufficiently cold to kill through freeze rupture alone. Within this region, some cells live for a few days and then succumb to apoptotic cell death. As clearly shown by the in vitro and in vivo data, apoptosis is a mechanism of cell death that may be exploited in an effort to improve the efficacy of cryosurgery. However, to date, few clinical reports have described apoptosis in the vicinity of the cryoablated tissue.
Technique -The Freeze-Thaw Cycle
Basic cryosurgical technique requires that the tissue is frozen rapidly, is thawed slowly and completely, and then is exposed to a second freeze cycle. The goal is to achieve a cell-lethal temperature in the target tissues, including a safe margin around the tumor. Every phase of the freeze-thaw cycle, including the cooling rate, temperature produced in the tissue, duration of freezing, Figure 4 : Bcl-2 overexpression affects the efficacy of the taxotere-freeze combination. PC-3 Neo (normal) and PC-3 Bcl-2 (Bcl-2 overexpressing) cells were exposed to either taxotere (1 μg/ml), freezing (-15 or -20 ºC), or the combination. Cell viability was assessed 1 day post thaw using the metabolic activity indicator alamarBlue™.
Figure 3:
Antiapoptotic Bcl-2 levels increase following freezing. PC-3 cells were exposed to freezing (-15 ºC). Proteins were isolated from the cell populations at the indicated time points postthaw, electrophoretically separated and probed for Bcl-2, Bax, and tubulin. Western blots were digitized and analyzed to quantify changes in protein level over time following treatment. and thawing rate, may be injurious. Repetition of the freezethaw cycle subjects the tissues again to the injurious elements and commonly is considered to be important to ensure proper destruction of the tumor. The characteristics of each of these phases of the cycle vary in relation to the distance from the heat sink, that is, the cryosurgical probe. The tissue close to the probe cools quickly, whereas the tissue at a distance from the probe cools more slowly in direct relationship to the thermal gradient established over distance. The second freeze is more rapid due to the decrease in the heat sink created by the first cycle. Current research continues to examine the components of the freeze-thaw cycle in an effort to assess their role in freezing injury and thereby increase the efficacy of cryosurgery (Klossner et al., in press) .
Rate of Tissue Cooling
The cooling rate should be as fast as possible because rapid cooling increases the probability of intracellular ice crystal formation, which is known to be lethal for cells. Intracellular ice formation typically occurs at cooling rates greater than 20 ºC per minute and is even more certain at faster cooling rates (28). Hong and Rubinsky have demonstrated that intracellular ice crystals form in tightly packed cells at even slower cooling rates (29). These variances in the rates at which intracellular ice will form suggest that the cooling rate may be less critical to cell injury than other factors.
In clinical practice, the cryosurgical probe should always be used at the lowest attainable temperature because fast freezing has a greater potential to produce intracellular ice. Colder probes or probes with increased freezing surface area will freeze a given volume of tissue more quickly. Whatever the probe temperature, much of the frozen volume will be subjected to only slow cooling rates, adding support to the notion that cooling rate cannot be considered the primary factor responsible for cryogenic injury.
Target Tissue Temperature
A prime factor in cryosurgical technique is the temperature produced in the tissues. Cells die in progressively greater numbers as the tissue temperature falls through the range of freezing temperatures. This effect can be summarized by a compilation of data from published reports by various researchers ( Figure 5 ). In a specific series of experiments with the PC-3 prostate cancer cell model, cells were frozen in vitro to study the effects of temperature on the molecular mechanisms underlying cell death (19, 22, 30) . In these experiments, cells were exposed to a range of temperatures from -5 ºC to -80 ºC. The data revealed a progressive decrease in cell survival as temperature lowered. Survival falls sharply around -20 ºC, yet some cells survive following exposure to temperatures of -80 ºC. While the sharp decrease in viability is clear, and it is evident that the majority of cells die as tem-peratures approach -30 ºC, many cells, even within the same tissue type, can survive at much colder temperatures. To further our understanding of cell specific response to freezing, a series of recent studies was performed to investigate the differences between prostate cancer cells. The data from this study indicated that androgen-dependent cells may be more sensitive to freezing injury than androgen-independent prostate cancers ( Figure 6 ). Though extensive cell death is produced at -20 ºC to -30 ºC, cell destruction is incomplete (31). Studies have shown that cancer cells are remarkably resistant to mild cryogenic injury, so tissue temperatures of about -40 ºC should be produced to assure complete destruction of the tumor tissues (12, 27, 32) .
Duration of the Freeze Cycle
Questions have arisen over the years about the duration of freezing; that is, how long should the tissue be held in the frozen state? While anecdotal evidence and physician instinct have guided timing in regard to clinical practice, few basic research studies have been conducted to provide lab-based evidence pertinent to duration (33). Recently, a study by Klossner et al. (in press ), using prostate cancer cells in vitro demonstrated a significant increase in cell death when the freeze duration was increased from five minutes to ten minutes ( Figure 7 ). In addition the study showed that passive thawing of the frozen tissue was more deleterious than active (rapid) thawing ( Figure 7) . A further set of experiments using prostate cancer cell lines demonstrated the increased lethal effect of a double freezethaw cycle, especially at the modest freezing temperature of -15 ºC ( Figure 8 ). These findings regarding temperature, hold times, thawing procedures, and cycle repetition are consistent with other reports and establish a basic scientific framework for the current surgical techniques and for continued procedural evolution.
The selection of a tissue temperature goal for cryosurgical treatment must include the recognition of thermal gradients in frozen tissue. As discussed above, the tissue close to a probe is frozen quickly to a cell-lethal temperature. The further from the probe, the slower the cooling rate and the warmer the freezing temperature. Mala et al. used a bioheat equation to evaluate the isotherms resultant from a cryosurgical procedure using MRI imaging (34). The isotherm model was constructed by creating frozen lesions in the liver of pigs. The -40 ºC isotherm enclosed 26% of the frozen volume, which demonstrates the need to expand the border of freezing a considerable distance beyond a neoplastic lesion. A later report by Mala et al., using MRI in patients with liver tumors, noted that excellent visualization of the frozen volume was provided and that the volume of frozen tissue contained within the -40 ºC isotherm was increased by about 42% with a second freeze cycle (35). Even the -20 ºC isotherm is located well within the frozen border. An important point to note is that, despite the double freeze, a peripheral margin remains in which absolute lethal temperatures will not be achieved. This fact drives the need for a freeze margin beyond the tumor limits in clinical application and for the continued exploration of adjunctive therapy to increase the efficacy of cryosurgery.
Adjunctive Combination of Chemotherapy and Cryotherapy
The use of cytotoxic drugs as an adjunctive agent may be the most promising approach to increase the kill efficacy of cryotherapy along the margin of the ice ball. Clarke et al. (19, 22) reported, using a prostate cancer cell line, that an initial sub-toxic exposure to agents such as 5-Flurouracil or Taxotere prior to the freezing insult increased the lethal affect of freezing at the warmer sub-freezing temperatures associated with the iceball periphery ( Figure 9 ). It was further demonstrated that while each of these combinations was effective over a large range of temperatures, even as warm as -5 ºC, the Taxotere/freezing combination exhibited greater efficacy than that of the 5-FU/freezing combination ( Figure 10 ). More recently, Clarke et al. demonstrated a profound effect on prostate cancer cell death by combining the cytotoxic agent TRAIL simultaneously with freezing. Furthermore, this combination was found to be considerably less toxic when applied to normal prostate cells in vitro (32). These in vitro reports indicate that it may be beneficial to administer chemotherapeutic agents prior to cryosurgery (19, 22, 36) . In these studies, it was found that the increased cell death in the adjunctive approach was due to an increase in apoptotic cell death following freezing. The combining benefit of 5-FU and freezing, increasing the rate of apoptosis, was recently demonstrated by Wang et al. in an in vivo mouse glioma cell model (37).
Clinical Implications
The cryosurgical treatment of prostatic cancer now has a forty year history (32). The first published application of cryosurgery to the prostate was by Gonder et al. (38) in 1964. The initial technique was associated with significant complications. For example, in the study by Bonney et al., 229 patients were followed for up to ten years after cryosurgery (39). Comparisons of these patients were made with those who underwent radical prostatectomy and radiation therapy. All treatment modalities showed similar survival rates. Cryosurgery showed advantages in the treatment of large bulky tumors. However, inadequate monitoring of the freezing process, due to unavailability of yet-to-be developed technology, resulted in major complications such as urethrocutaneous and recto-urethral fistulas at much higher rates than those seen with the other therapeutic modalities. These complications initially limited the acceptance of cryosurgery as a treatment modality for prostate cancer.
Since its inception, cryoablation has undergone significant technical advancements, and has evolved as an effective treatment modality for a number of cancers. Substantial technical modifications were developed in the 1990's (40-42), followed by the development of new cryosurgical apparatus, imaging techniques, and adjunctive devices to improve the applicability and efficacy of cryotherapy. Technical improvements, such as the use of new multiprobe devices and the development and utilization of a protective urethral warming catheter may be cited as significant milestones in the evolution of cryosurgical technique (43) (44) (45) . Better selection of patients, with appropriate staging of disease, has substantially improved overall results. The evolution of cryosurgical techniques, including improved trans-rectal ultrasonography of the prostate and the use of urethral warmers has made complications such as incontinence, urethral sloughing, and fistulas uncommon (40, 43, 46) . For example, urethro-rectal fistula, common in earlier years, is now rare (<1%) as a result of improved monitoring techniques and greater clinical experience with prostatic freezing. A recently published multi-center study of 975 patients comparing cryosurgery to a published series on radiotherapy using similar risk stratification and failure criteria, showed cryosurgery yielded results similar to both external-beam radiation therapy and brachytherapy (47). The study stratified patients into three groups. The low-risk group was defined as Stage T2a or lower, PSA 10.0 ng/mL or less, and Gleason Sum score of 6 or less. The moderate risk group was defined as patients with any one of the following: Stage T2b or greater, PSA greater than 10.0 ng/mL, or Gleason Sum score of 7 or greater. The high-risk group included those with two or three of the above factors. The low-risk group had a 5year biochemical recurrence-free survival of 76% with cryosurgery, 75% to 87% for brachytherapy, and 67% to 81% for conformal radiation therapy. Comparable results were noted also for the medium and high-risk groups. In a review of 370 patients treated with cryosurgery as primary therapy for stage T1-T3 prostate cancer. A study by Cohen et al. (in press ) notes 10-year biochemical disease free survival using a nadir plus 2 definition of 68.4%, 74.2%, and 36.2%, respectively, for low, moderate, and high risk presentations. The median follow up period was 12.2 years, which is the longest term of follow up for a group of prostate cryosurgery patients reported to date. Table I also indicates the oncologic outcomes for salvage cryosurgery, typically performed for men who fail to respond to external beam radiotherapy and/or brachytherapy and who are believed to still have locally confined disease. The out-comes for cryosurgery continue to improve both in terms of oncologic efficacy and an improved side effect profile (55-57). Nevertheless, despite improvements and relative effectiveness of cryotherapy, the incidence of positive biopsies after prostate cryosurgery is about 10 to 20% (47, 49, 53, 58, 59) . Salvage cryosurgery, that is, treatment for persistent disease after irradiation, is associated with a positive biopsy rate of 0 to 40% (60-63, 67).
As the 1990's ended, liquid nitrogen was replaced by argon utilizing the Joule-Thomson effect for cooling, which has completely revolutionized the technique of cryosurgical ablation of the prostate (64). The argon-cooling apparatus is compact, portable, and computerized, allowing more precise control of the ice-ball formation with the ability to almost immediately switch from freeze to thaw Figure 6 : Effects of androgen-dependence on viability of prostate cancer cells following freezing. Androgen-independent and -dependent prostate cancer cells were exposed to a range of freezing temperatures (-5 to -40 ºC) and cell viability determined. Cell viability was assessed over a 5 day post thaw using the metabolic activity indicator alamarBlue™. Figure 7 : Effect of freeze duration on post-thaw viability of prostate cancer cells. PC-3 and LNCaP were frozen at -15 ºC for 5, 10, and 20 minutes followed by passive or active thawing. Day 1 viability was assessed post-freeze using the metabolic indicator alamarBlue™. LNCaP cell line showed a greater susceptibility to cryoablation than PC-3. 
Assessment of Freeze Cycle (-15 ºC) on Human Prostate Cancer (PC-3 and LNCaP)

Figure 9:
Post-thaw recovery of PC-3 cells following exposure to freezing or the indicated chemo/cryo combination. Cells were either exposed to freezing (-15 ºC) or in combination with 5-FU, taxotere, etoposide, cisplatin, or folinic acid. Cell viability was assessed using the membrane integrity calcein-AM assay over a 14 day recovery period.
Figure 10:
Taxotere/freezing combination exhibits greater efficacy than that of the 5-FU/freezing combination. PC-3 cells were exposed to either drug only, freezing (-5 to -40 ºC), or the combination. Cell viability was assessed post-freeze using the metabolic indicator alamarBlue™.
while maintaining control of probe temperature to approximately one degree Celsius (55). The development of needlesharp tipped, ultra-thin 17 gauge cryoprobes has facilitated the placement of the probes, thereby decreasing operative time (44, 65, 66) . Cryosurgery in 2007 is truly a minimally invasive procedure with direct transperineal skin penetration and precise insertion of the cryoprobes into the prostate through a conventional brachytherapy-type grid template, making this a safe and effective outpatient procedure (71).
These technical advances have led to dramatic improvement in the application of cryosurgery and clinical results that have stimulated the American Urological Association to recognize cryoablation as a therapeutic option for the treatment of localized prostate carcinoma (72). Data from Allegheny General Hospital (AGH) demonstrate 10-year undetectable PSA-response rates to cryosurgery including salvage procedures at 57%, i.e., comparable with results of salvage radical prostatectomy (73). Han et al. presenting multicenter data using a third generation cryosurgical device, confirmed further prog-ress regarding the efficacy of the procedure (58). This collaborative group used the definition of biochemical disease-free survival (bDFS) as a PSA level of ≤ 0.4 ng/ml after a review of the radiation oncology literature revealed a wide range of "acceptable" PSA nadir values (from 0.2 to 4.0 ng/ml). Recent literature has suggested that patients who reached a PSA nadir of 0.4 ng/ml or less have the highest probability of cure after external beam therapy (58, 66, 68) . As a result the same value was chosen to define bDFS after cryosurgery.
Due to the high number of recurrent prostate cancers, after limited radiation therapy in the United States, there has been an expanded role for cryosurgery in these patients. Salvage cryosurgery for radio-recurrent prostate cancer offers durable intermediate-term oncologic results. Estimated 12year cancer-specific survival in this high risk population is over 80%, and over two thirds of patients remain biochemically disease free. Complication rates have been reduced significantly with the introduction of improved ultrasound guidance, urethral warming devices, and 2 nd generation ar- gon-based systems. Rectourethral fistulae have been greatly reduced with these modern techniques. The efficacy and side effect profile of salvage cryosurgery compares favorably with salvage prostatectomy and is the preferred method of treating radio-recurrent, localized prostate cancer particularly in those with significant comorbidities.
The growing literature base, has led to the acceptance of cryosurgery as an option for the management of cancer of the prostate. The technical advances leading to the development of third-generation cryosurgical instrumentation and technique along with better patient selection have dramatically improved the clinical results of cryosurgery for localized prostate cancer with acceptable cancer control, though the rate of persistent disease shows the need for further study and improvement in therapy.
Modern Cryotherapy
Current technology for freezing the prostate gland commonly uses a template for placement of thin, 17 gauge needle probes (Galil, Inc.) into the gland in a fashion similar to that used for prostatic brachytherapy (53-58) or the free-hand insertion of larger diameter probes (Endocare, Inc.). Treatment planning with the use of computers and simulation models to measure the dimensions of the gland and determine the required probe positions may continue to improve the accuracy and efficacy of the technique (74-76). The challenge facing cryosurgery, as with all cancer treatment modalities, is to improve its efficacy, specifically related to increasing kill at the warmer subfreezing temperatures, while reducing the need for a margin of intrusive freezing beyond the tumor boundary. In clinical use, an important technical point to achieving homogeneous cell death is to place adjacent cryoprobes close enough to one another so that there is sufficient overlap of the isotherms.
The tissue should be made as cold as possible as fast as possible by following a strategy of using all of the probes (needles) inserted into the prostate together and at as high a power as possible for as long as the bounds of safety allow. In other words, with the current technology, temperatures within the target organ drop fastest when all probes/needles are activated simultaneously at maximum power. However, effective cryosurgical ablation of the prostate is accomplished with activation of cryoprobes placed in the anterior followed by sequential activation toward the gland's posterior.
Cryosurgical techniques are exploring new directions to promote a better quality of life after therapy (69, 70). One effort that has import to the patient is the preservation of sexual function following prostate cryosurgery. The neurovascular bundles responsible for penile erection are adherent to the posterolateral aspect of the prostatic capsule. During prostate cryosurgery, the aim of the treatment is to kill all of the prostate tissue up to the prostatic capsule while differentially preserving the function and structure of the neurovascular bundles. The ability of peripheral nerve tissue to regenerate following cryoinjury is not a new finding. Robinson et al. (77) reported recovery of sexual function in 5 of 38 (13%) patients with (another) 13 of 38 (34%) patients being able to have intercourse three years after prostate cryosurgery, suggesting that the periprostatic nerve bundle can recover after freezing. Because of the high rate of impotence after conventional cryosurgery (up to 80-90%) for both primary and salvage procedures, the concept of nerve-sparing cryoablation has been recently developed in order to avoid this serious side effect in potent patients. This is done either by keeping the neurovascular bundles warm by maintaining cryoprobes positioned adjacent to the neurovascular bundles in a heating mode by circulating helium during the freezing cycle. The use of local cryoprotectants (i.e., injecting saline or other cryoprotectants along the route of neurovascular bundles) is under investigation.
The other attractive feature in modern prostatic cryosurgery is focal ablation of a single (unifocal) small volume prostate cancer. In parallel with breast cancer in women, this conceptual approach of "male lumpectomy" may deserve attention and further research (78, 79). In the near future when imaging modalities may be able to delineate the cancer within the prostate and saturation biopsies may detect a unifocal tumor with high probability, patient selection will determine the efficacy of focal ablative therapy.
Imaging the Cryosurgical Procedure
The application of cryosurgery relies on guidance from information derived from the imaging techniques. Ultrasound, as originally used in prostate cryosurgery, allows for monitoring of ice ball growth progression, but has significant limitations because the practitioner cannot see beyond the nearest ice plane of frozen tissue. The resulting image is two-dimensional because acoustic shadowing precludes visualizations of the extent of freezing behind the ice front (80). Three-dimensional ultrasound may well alleviate this problem (81-84). Another limitation of ultrasound occurs because the image provides no information about target tissue temperature (85), which causes difficulty in making real-time determination of where the critical -40 ºC isotherm is within the ice ball. To address the issue of thermal monitoring, the use of thermocouples in conjunction with ultrasound has added an increased level of certainty to the success of prostatic cryosurgery.
Next Generation Imaging Techniques
New directions in imaging for cryosurgery include computerized tomography (CT), magnetic resonance imaging (MRI), and electrical impedance tomography (EIT). CT has the benefit of showing the entire cross sectional image of the frozen tissue. The images are made at intervals of a minute or two, which is not real time but still within the realm of usefulness (86). One issue, which will need to be contended with application of CT imaging, is the related procedural cost of use. Another potential visualization modality being explored is that of MRI. MRI provides a three-dimensional view of the volume of frozen tissue and has shown promise as a clinically valuable monitoring technique in cryosurgery (87-91). However, with MRI the necessity of MRI-compatible cryoprobes, made of non-ferromagnetic materials has limited utilization of this approach to date. One intriguing aspect of MRI is that from the data gleaned, the temperature within the frozen volume can be established using mathematical models (92) (93) (94) . The techniques of MRI are still evolving, as are the MRI contrast agents (95). Harada et al. recently demonstrated the usefulness and safety of MRI-guided cryosurgery for renal tumors (96). However, the probability of extensive or routine clinical use of MRI-guided cryosurgery in the near future is remote because of the expense of the equipment and need for apparatus compatible with special needs related to the electromagnetic field. In addition to CT and MRI, the use of electrical impedance tomography (EIT) has been proposed as a method of monitoring the freezing of tissue (97). EIT provides a global image by introducing low amplitude AC currents into the body; thus, measuring the electrical potentials on the body surface. These potentials are then recorded and analyzed to create a tomographic image (98-100). While interesting, this approach to imaging needs further development and testing prior to use in cryosurgical procedures.
Thermocouple Monitoring
The use of thermocouples to monitor tissue temperature during freezing has emerged as an important adjunct to the imaging techniques. Needle-mounted thermocouples have proven accurate and useful for thermal monitoring, especially when inserted in critical areas, such as the prostatic capsule or in the apical portions of the prostate (48, 101). Their use allows for the confirmation that lethal temperatures have been achieved in the target tissue or that injurious temperatures have not been reached in critical areas, such as in the wall of the rectum. It is important to note that thermocouples measure point sources of temperature within the tissue. As such, these temperatures cannot be extrapolated easily to the entire volume of the cryosurgical lesion.
Procedural Limitations
A major concern in prostatic cryosurgery relates to anatomical considerations, including the proximity of the gland to the rectum and the need to preserve the urethra. Aggressive freezing, that is, producing a temperature of -40 ºC or colder throughout the prostatic capsule necessitates the intrusion of the ice ball into adjacent tissues, which may lead to complications such as impotence, incontinence, or fistula.
Constraints on cryotherapy are imposed by the need to protect the rectum (and avoid fistula formation) and the urethra (and avoid sloughing and incontinence). These limitations preclude aggressive freezing therapy and thereby may contribute to a risk of persistent disease within the margin of the prostate. So methods must be developed to improve the efficacy of cryosurgery while using less aggressive freezing technique, near these vulnerable areas.
Adjunctive Approaches: Management of the Ice Ball Margin
As with most therapeutic approaches to disease, many facets of cryosurgery of the prostate gland are susceptible to improvement (102). The potential optimization of cryosurgical technique extends beyond improvements in freezing and imaging techniques. A major area of need is the improvement in the efficacy of cryosurgery in the border zone of the cryogenic lesion where the tissue temperature is warmer than -20 ºC. Though repetition of the freeze-thaw cycle (dual freeze) likely brings the lethal temperature close to -20 ºC, a significant number of cells in the periphery of the cryogenic lesion may survive freezing. It is for this reason that adjunctive approaches are needed.
Adjunctive therapy, which may take the form of irradiation, cancer chemotherapeutic drugs, apoptotic promoters, or immunological potentiators, have been shown to increase the efficacy of cryosurgery for many tumors. Radiotherapy often is used in the case of cryosurgery failure, but seldom is it used as a planned adjunctive therapy. Experiments in vitro have demonstrated that cooled cells have a greater sensitivity to irradiation (103, 104). However, the timing of delivery of irradiation has not been developed for a clinical therapeutic program. view of this diversity of responses, one can only conclude that this subject requires further research (114).
The most common adjunctive therapeutic approach is the use of cytotoxic drugs. Agent selection should be appropriate to the type of tumor. The timing of administration is currently an area of active investigation. Commonly, drugs have been administered weeks to months before or after cryosurgery, but recent studies suggest that drugs should be given just prior (within a few days), during and/or immediately after freezing. The series of reports by Clarke et al. have demonstrated that the additive effects of subclinical doses of cytotoxic agents and temperatures consistent with those measured in the prostate capsule yield maximum cell kill when the cytotoxic agent is applied 1-4 days prior to freezing (19, 22, 30) .
A metronomic schedule of administration may be effective. Continuous low dose chemotherapy, being active against endothelial cells, is thought to inhibit tumor angiogenesis (115, 116) . This style of drug delivery may be effective in the treatment of prostatic cancer because the cells proliferate slowly in the majority of cases, so that resistance to the many drugs that target dividing cells is common. An alternate and perhaps better method of cytotoxic drug use is to deliver the drug directly into the tumor during thawing. Local chemotherapy also can be given by placing the drug on a carrier, which is placed into the track after removal of the probe (98). With this method, the drug remains in the local area and does not gain significant access to the circulation, thereby, minimizing the toxic side effects to the patient. Mir and Rubinsky have shown that freezing alters membrane permeability (117). Since cell membranes are important barriers to drug therapy, this is another reason to expect that local chemotherapy may prove useful as an adjunct to cryosurgery. Further research is needed to define the optimal mode of cytotoxic drug use, but adjunctive chemotherapy is likely to increase the efficacy of cryosurgery.
Summary
Cryosurgery requires subjecting tissue to freezing temperatures. Cellular and tissue injury are produced by a sequence of destructive effects, beginning with tissue cooling, metabolic disruption, ice crystal formation, and cellular constituent fragmentation. After thawing, microcirculatory failure and the associated ischemia adds to cell death, resulting in a coagulative necrosis. Physical processes of destruction are effective immediately, but physiological-based detrimental effects, including cytokine release and induction of apoptosis and necrosis, produce a damaging effect over several days.
The basic principles of cryosurgery for tumors are fast cooling of the tissue to a cell-lethal temperature, slow thawing, and repetition of the freeze-thaw cycle. To achieve therapeutic efficacy, careful attention must be given to the freeze-thaw cycles. Ideally a temperature of -40 ºC should be produced in the normal tissue around a tumor. This procedure should ensure that all portions of the tumor are subjected to a temperature of -40 ºC or colder. This stringent requirement is not easy to achieve and in many cases not practical. Fortunately, repetition of freezing raises the cell-lethal temperature to some extent. In addition, prolonging the duration of freezing increases the certainty of cell destruction.
Cancer of the prostate gland presents special problems for cryosurgical techniques. The proximity of the prostate to the rectum and the relationship to the urethra and sphincter provide a hindrance to aggressive freezing techniques. The use of the urethral warmer protects the urethra and to some extent the sphincter, and reduces the incidence of incontinence after cryosurgery, but permits the survival of some periurethral glands. The desire to avoid injury to the rectum reduces the extension of freezing through the prostatic capsule. These limitations imposed on prostatic cryosurgery makes the use of adjunctive therapy to improve efficacy imperative.
Experiments on the molecular basis of cell death associated with cryosurgery have demonstrated the potential value of adjunctive cytotoxic chemotherapy for prostatic cancer. The expected effect of adjunctive molecular-based therapy is to increase the extent of injury to cells in the peripheral portion of the cryogenic lesion. Differences in cell sensitivity to androgens and cryotoxic drugs also influence adjunctive therapy. Further research should lead to a better understanding of the molecular mechanisms involved in cryosurgery and adjunctive therapy, which in turn should increase the efficacy of cryosurgery for tumors.
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